Patents by Inventor Claudia Wall

Claudia Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT
    Publication number: 20220340674
    Abstract: The invention relates to a method for the production of a bispecific CD30×CD16A antibody construct comprising a first binding domain for Fc?RIIIa comprising the steps chromatographically capturing the antibody construct from a solution; eluting the antibody construct from the capture matrix; reducing the pH in the solution of the eluted antibody construct to low pH, incubating the antibody construct under these conditions for at least 40 h and neutralizing thereafter.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 27, 2022
    Inventors: Claudia WALL, Michael WEICHEL
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20210024654
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 18, 2020
    Publication date: January 28, 2021
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20180291113
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: October 27, 2017
    Publication date: October 11, 2018
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9803029
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 31, 2017
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160194409
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: November 10, 2015
    Publication date: July 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160002333
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 9, 2015
    Publication date: January 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9212225
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: December 15, 2015
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky